Pulse Biosciences, Inc. (PLSE)

Market Cap	911.47M
Revenue (ttm)	86,000
Net Income	-74.73M
EPS	-1.13
Shares Out	67.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,738
Open	13.55
Previous Close	13.55
Day's Range	13.32 - 13.83
52-Week Range	12.56 - 25.00
Beta	1.68
Analysts	Buy
Price Target	22.00 (+63.57%)
Earnings Date	Nov 5, 2025

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-ena...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 18, 2016
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: PLSE
• Website: https://www.pulsebiosciences.com

Analyst Summary

According to one analyst, the rating for PLSE stock is "Buy" and the 12-month stock price target is $22.0.

Price Target

$22.0

(63.57% upside)

Analyst Consensus: Buy